Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Acquired resistance to cetuximab, an epidermal growth factor receptor (EGFR) antibody, limits its clinical efficacy in head and neck and colorectal cancers.
• A key resistance mechanism involves mutations in the EGFR epitope, preventing cetuximab binding.

Purpose of the Study:

• To investigate if necitumumab, another EGFR antibody, can bind to EGFR variants with cetuximab-resistance mutations.
• To elucidate the structural basis of necitumumab binding to mutated EGFR.
• To assess the potential of necitumumab in patients resistant to other EGFR inhibitors.

Main Methods:

• X-ray crystallography was used to determine the structure of necitumumab Fab bound to an S468R mutant EGFR domain III.
• Binding assays were performed to test necitumumab's interaction with various cetuximab- and panitumumab-resistant EGFR variants.
• A computational approach was developed to predict antibody binding to EGFR epitope mutations.

Main Results:

• Necitumumab successfully binds to EGFR harboring the S468R mutation, a common cetuximab-resistant substitution.
• The crystal structure reveals necitumumab accommodates the mutation within a pre-existing cavity in its binding site.
• Necitumumab demonstrates binding to most tested EGFR variants resistant to cetuximab and panitumumab.
• A computational method accurately predicts the impact of EGFR epitope substitutions on antibody binding.

Conclusions:

• Necitumumab may offer a therapeutic option for patients with cancers resistant to cetuximab or panitumumab due to EGFR epitope mutations.
• The structural feature of a large paratope cavity in necitumumab may confer broader resistance to epitope mutations.
• A predictive computational tool can aid in identifying effective antibodies against emerging EGFR resistance variants.